Heart Views最新文献

{"title":"Characteristics and Outcomes of Patients Undergoing Drug-coated Balloon Angioplasty: The Initial 4-year Experience in Qatar.","authors":"Rasha Kaddoura, Jassim Z Shah, Mohamed Izham Mohamed Ibrahim, Haisam Alsadi, Ihsan Rafie, Sumaya Mehdar A Alsaadi Alyafei, Abdul Rahman Arabi, Fahad Al-Kindi","doi":"10.4103/heartviews.heartviews_77_25","DOIUrl":"10.4103/heartviews.heartviews_77_25","url":null,"abstract":"<p><strong>Background: </strong>A drug-coated balloon (DCB) allows treating the coronary artery lesions without permanent implantation of a metallic stent. International guidelines recommend DCB for the treatment of in-stent restenosis (ISR). Although DCB showed promising results in treating ISR, their role is still not well established in the broader clinical practice.</p><p><strong>Objective: </strong>In this short report, we describe our institution's four-year initial experience in using DCB angioplasty, and compare the characteristics and outcomes of the patients treated with DCB with those treated with drug-eluting stent (DES) for ISR.</p><p><strong>Methods: </strong>This is a single-center retrospective study of patients who underwent coronary angioplasty with either DCB or DES from January 1, 2018 to November 30, 2021 at the Heart Hospital in the State of Qatar.</p><p><strong>Results: </strong>A total of 572 patients with ISR were recruited, 132 and 440 patients were in the DCB and DES group, respectively. In the DCB group, the median age was 57.9 years and there were 117 (88.6%). There was no significant difference between the DCB and DES groups in term demographics, comorbidities, coronary angiography indication or characteristics, and clinical outcomes. With regards the clinical outcomes, 13 patients (9.8%) underwent angioplasty for ACS and chest pain in the DCB group. The median time to the first event was a median of 480 days (16 months).</p><p><strong>Conclusion: </strong>The use of DCB is increasing in Qatar. The initial experience was limited to its use in ISR. Patient characteristics, angiographic characteristics, and clinical outcomes in the DCB group did not significantly differ from those in the DES group. More studies are needed to evaluate the use of DCB in wider indications.</p>","PeriodicalId":32654,"journal":{"name":"Heart Views","volume":"26 3","pages":"137-143"},"PeriodicalIF":0.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12697751/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145757741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity Paradox Occurs in Non-ST-elevation Myocardial Infarction for Overweight and Obesity but Not for Morbid Obesity.","authors":"Mehrtash Hashemzadeh, Amir Parsa Abhari, Mohammad Reza Movahed","doi":"10.4103/heartviews.heartviews_98_25","DOIUrl":"10.4103/heartviews.heartviews_98_25","url":null,"abstract":"<p><strong>Introduction: </strong>The obesity paradox has been observed in patients with cardiovascular disease. The goal of this study was to evaluate if obesity has a protective effect in patients presenting with non-ST-elevation myocardial infarction (NSTEMI).</p><p><strong>Methods: </strong>Using a large Nationwide Inpatient Sample (NIS) database, we evaluated mortality in patients with NSTEMI based on weight categories in adults.</p><p><strong>Results: </strong>A total of 3,597,279 NSTEMI patients were found in the database over the age of 18 years. We found that overweight and obesity, followed by morbid obesity, had the lowest mortality using univariate (overweight mortality of 3.2% vs. obesity mortality of 3.78% vs. morbid obesity mortality of 5.69% vs. 7.8% of normal weights), whereas cachexia was associated with the highest mortality in univariate analysis (cachexia 21.82%). Using multivariate analysis adjusting for baseline characteristics and comorbidities, those relations remained unchanged (cachexia Multivariate Odds ratio (MVOR): 2.56, confidence interval [CI]: 2.41-2.73, <i>P</i> < 0.001; overweight MVOR: 0.49, CI: 041-0.59, <i>P</i> < 0.001; obesity MVOR: 0.6, CI: 0.58-0.63, <i>P</i> < 0.001; and morbid obesity MVOR: 0.94, CI: 0.9-0.98, <i>P</i> = 0.004).</p><p><strong>Conclusion: </strong>We observe an obesity paradox in patients with NSTEMI, showing that overweight, followed by obesity and morbid obesity, have the lowest mortality, with cachexia having the highest mortality.</p>","PeriodicalId":32654,"journal":{"name":"Heart Views","volume":"26 3","pages":"163-169"},"PeriodicalIF":0.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12697747/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145757810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Independent Predictors of Receiving Pacemaker with Trends of Complications and Mortality in the United States with Higher Prevalence in Male and Caucasians.","authors":"Mohammad Reza Movahed, Nandini Sodhi, Mehrtash Hashemzadeh","doi":"10.4103/heartviews.heartviews_157_24","DOIUrl":"10.4103/heartviews.heartviews_157_24","url":null,"abstract":"<p><strong>Introduction: </strong>Risk factors for needing a pacemaker have not been well studied. The goal of this study was to evaluate predictors, complications, trends, and mortality rates of pacemakers in adults.</p><p><strong>Methods: </strong>We utilized the International Classification of Diseases, Tenth Revision, and Clinical Modification coding for this study. We evaluated clinical predictors of pacemaker insertions, their complications, and mortality using the Nationwide Inpatient Sample database for the years 2016-2020 in adults.</p><p><strong>Results: </strong>A total of 647,435 patients had a pacemaker insertion at an average age of 76 years old (±11.48 years). Significant independent clinical predictors for pacer insertion were non-ST-elevation myocardial infarction: 4.3% versus 2.4%, odds ratio (OR), 1.85; 95% confidence interval (CI), 1.80-1.91; <i>P</i> < 0.001, hypertension: 84.40% versus 55.95%, OR, 4.26; 95% CI, 4.19-4.34; <i>P</i> < 0.001, hyperlipidemia: 59.59% versus 2.85%, OR, 3.01; 95% CI, 2.97-3.05; <i>P</i> < 0.001, atrial fibrillation/flutter: 45.89% versus 15.35%, OR, 4.68 95% CI, 4.62-4.74; <i>P</i> < 0.001, diabetes: 35.76% versus 27.20%, OR, 1.49; 95% CI, 1.47-1.51; <i>P</i> < 0.001, chronic kidney disease: 30.00% versus 17.70%, OR, 1.99; 95% CI, 1.97-2.02; <i>P</i> < 0.001, smoking: 29.81% versus 23.10%, OR, 1.41; 95% CI, 1.31-1.43; <i>P</i> < 0.001, chronic obstructive pulmonary disease: 17.63% versus 16.17%, OR, 1.11; 95% CI, 1.09-1.13; <i>P</i> < 0.001, valvular heart disease: 17.19% versus 3.76%, OR, 5.31; 95% CI, 5.21-5.41; <i>P</i> < 0.001, systolic heart failure: 12.94% versus 6.99%, OR, 1.98; 95% CI, 1.94-2.02; <i>P</i> < 0.001, prior percutaneous intervention: 11.70% versus 5.45%, OR, 2.30; 95% CI, 2.26-2.34; <i>P</i> < 0.001, obesity: 10.05% versus 8.57%, 1.19; 95% CI, 1.17-1.22; <i>P</i> < 0.001, history of coronary artery bypass grafting: 10.05% versus 4.32%, OR, 2.48; 95% CI, 2.43-2.52; <i>P</i> < 0.001, STEMI: 1.45% versus 2.66%, 1.45% OR, 1.86; 95% CI, 1.79-1.93; <i>P</i> < 0.001, history of cardiomyopathy: 0.74% versus 0.39%, OR, 1.90; 95% CI, 1.78-2.03; <i>P</i> < 0.001, and endocarditis: 0.15% versus 0.09%, OR, 1.77; 95% CI, 1.53-2.04; <i>P</i> < 0.001. Pacemaker complication rates were around 2% with a mortality of 1.44%.</p><p><strong>Conclusion: </strong>We found many predictors for the need for pacemaker insertion. Mortality and complications have remained low over recent years with higher prevalence in males and Caucasians.</p>","PeriodicalId":32654,"journal":{"name":"Heart Views","volume":"26 2","pages":"102-107"},"PeriodicalIF":0.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12571095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145410322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-density Lipoprotein Cholesterol Level on Admission and After One Year with Clinical Outcomes in Patients Admitted with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.","authors":"Emaad Salim Al Shibli, Panduranga Prashanth","doi":"10.4103/heartviews.heartviews_54_25","DOIUrl":"10.4103/heartviews.heartviews_54_25","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Percutaneous coronary intervention (PCI) is the established treatment for acute coronary syndromes (ACS). Despite optimal procedural outcomes with advanced hardware, recurrent coronary events within 1-year are known to occur. In-patients with documented ACS, the American College of Cardiology/American Heart Association recommends use of high intensity statins (which lowers low-density lipoprotein cholesterol (LDL-C) by ≥50%), i.e., 40-80 mg for atorvastatin though the European guidelines have recommended a LDL-C level of 1.4 mmol/l or below as a core preventative measure for future events.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;The aim of the study is to find proportion of patients with European guideline recommended target of LDL-C &lt;1.4 mmol/L during the first presentation of ACS, and after 1 year, and to correlate with 1-year clinical outcomes in patients undergoing PCI.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This is a retrospective observational study at a tertiary care referral hospital of ACS patients who underwent PCI from January 1, 2019, to December 31, 2019. A total of 371 patients were included in the study who had a baseline and 1-year lipid profile data. Patients were divided into two groups, LDL-C ≤1.4 mmol/L (Group 1) and more than 1.4 mmol/L (Group 2) and compared for major adverse cardiovascular events (MACE).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;At presentation, 354 (95%) patients presented with LDL-C level above 1.4 mmol/L. Mean LDL-C level at presentation and at 1-year was high at 3.05 ± 1.11 and 2.36 ± 1.06 mmol/L, respectively. Majority of the patients were on atorvastatin 40 mg at discharge (77%). At 1 year, only 15% had LDL-C level below 1.4 mmol/L and 79% were still on 40 mg of atorvastatin. Overall, 51% of the cohorts were asymptomatic and 32% presented with MACE. Majority of MACE occurred in Group 2 80% of total MACE compared to 20% in Group 1. Unadjusted odds ratios for myocardial infarction, cardiac death, and target vessel revascularization by PCI in Group 2 were not significant. However, they were high for cerebrovascular accident (CVA) (4.4) and coronary artery bypass surgery (1.9). Seventy-two percent of patients had 50% reduction in their LDL-C from baseline but not reaching a goal of &lt;1.4 mmol/L. However, there was statistically significant increase in CVA and cardiac death in patients with no 50% reduction (&lt;i&gt;P&lt;/i&gt; &lt; 0.05).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;In a tertiary hospital large-volume ACS-PCI center, more than two-thirds of patients had their mean LDL-C level at presentation and 1-year beyond the recommended target level of &lt;1.4 mmol/L, with one-third of patients developing 1-year MACE. A strategy of only taking a high-intensity statin was not adequate in reaching the LDL-C goal of &lt;1.4 mmol/L though two-thirds of patient achieved 50% reduction in their LDL-C. There is an urgent need to educate physicians in the region to follow the recommended target LDL-C of 1.4 mmol/L and escalate ","PeriodicalId":32654,"journal":{"name":"Heart Views","volume":"26 2","pages":"80-87"},"PeriodicalIF":0.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12571096/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145410251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subclinical Cardiac Dysfunction in Childhood Nephrotic Syndrome: A Case-control Study.","authors":"Rajkumar Motiram Meshram, Somnath M Mohite, Sagar Chopade","doi":"10.4103/heartviews.heartviews_51_25","DOIUrl":"10.4103/heartviews.heartviews_51_25","url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular risk in nephrotic syndrome (NS) is attributed to persistent proteinuria, systemic inflammatory activation, and hyperlipidemia. Due to the limitations of conventional echocardiography, the Tei index is useful to detect subclinical cardiac dysfunction.</p><p><strong>Objectives: </strong>To determine the cardiac dysfunction in children diagnosed with NS.</p><p><strong>Materials and methods: </strong>This case-control study was conducted at Government Medical College, Nagpur, for 1 year in 36 children with NS of age group 1-12 years as cases and 36 age- and sex-matched children without kidney/cardiac diseases or illness which influences kidney/cardiac function selected by simple random method as a control. Demographic, clinical, and anthropometric data were collected. Hematological, biochemical investigations, and electrocardiography (ECG) were performed. Conventional two-dimensional echocardiography and tissue Doppler imaging (TDI) were performed by a cardiologist using ALPINION 5 color Doppler ultrasound machine. Conventional M-mode, B-mode, and Doppler parameters were measured as per the American Society of Echocardiography guidelines. Chi-square test and Student's <i>t</i>-test were used to compare between cases and controls. Pearson correlation coefficient was used to correlate between the variables of TDI findings. <i>P</i> <0.05 was considered statistically significant.</p><p><strong>Results: </strong>Demographic and clinical variables were comparable in cases and controls except body mass index and diastolic blood pressure, which were significantly higher in cases. Serum albumin was significantly low (<i>P</i> < 0.0001), while the total mean cholesterol (<i>P</i> = 0.0005), triglycerides (<i>P</i> = 0.0001), and low-density lipoprotein (<i>P</i> = 0.01) were significantly higher in cases compared to controls. ECG and conventional echocardiographic findings were nonsignificant between cases and controls. Both left and right ventricular Tei indices were statistically significantly high in cases compared to control (<i>P</i> < 0.0001). Serum albumin was inversely correlated with a high Tei index of both ventricles.</p><p><strong>Conclusion: </strong>Subclinical cardiac dysfunction is early evident by TDI compared to conventional echocardiography, and the Tei index is inversely associated with serum albumin. This implies timely recognition of cardiac subclinical dysfunction and to prevent the progression of cardiovascular disease to heart failure.</p>","PeriodicalId":32654,"journal":{"name":"Heart Views","volume":"26 2","pages":"108-115"},"PeriodicalIF":0.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12571090/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145410281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Left Coronary Artery Lumen Measurements in Relation to Anthropometric Factors: A Single-center Study, Saudi Arabia.","authors":"Abdulaziz Algethami, Mousa Aljohni, Abdulrahman AlQahtani, Hussam Aradh","doi":"10.4103/heartviews.heartviews_146_24","DOIUrl":"10.4103/heartviews.heartviews_146_24","url":null,"abstract":"<p><strong>Introduction: </strong>Left main coronary artery (LMCA) revascularization has been indicated when the mean luminal area (MLA) measured by intravascular ultrasound (IVUS) is <6 mm². Few studies showed that the cut point for revascularization is less than that in Asian population. In this study, we studied the relationship between the LMCA area measured by IVUS and height and weight measurements to approximate the correlation.</p><p><strong>Methodology: </strong>A cross-sectional analysis study included all patients who underwent IVUS assessment in King Abdulaziz Cardiac Center, Riyadh, Saudi Arabia, between 2015 and 2021. Patients with significant LMCA disease (>50%), calcification prevent clear measurement of LM artery media layer or any LMCA previous stents, and poor IVUS acquisition were excluded. The LMCA area measured by IVUS at the mid-shaft of the artery was investigated for correlation with patients' height, weight, body mass index (BMI), and body surface area (BSA).</p><p><strong>Results: </strong>A total of 242 patients were included (20.2% of females with a mean age of 59.3 ± 12.1 years). The mean LMCA minimum luminal area (MLA) is 22.2 ± 5.51 mm². There is no significant difference between gender (female MLA 21.2041 mm² vs. male MLA 22.4021 mm² (<i>P</i> = 0.174). There is a significant correlation between LMCA area and height, with a correlation coefficient of 0.21 and <i>P</i> = 0.0008; by simple linear regression, there is a 1.38 mm² increase in LMCA area for every 10 cm increase in height. There is also a significant correlation between LMCA area and weight with a correlation coefficient of 0.19 and <i>P</i> = 0.0025; by simple linear regression, there is a 0.7 mm² increase in LMCA area for every 10 kg increase in weight.</p><p><strong>Conclusion: </strong>The diameter values of the LM in our population sample aligned with those of other populations. There was no statistically significant correlation to age, gender, BMI, or BSA. However, we discovered a weak but statistically significant correlation between height and weight. The clinical importance of the correlation needs to be further investigated in a larger population-based study.</p>","PeriodicalId":32654,"journal":{"name":"Heart Views","volume":"26 2","pages":"75-79"},"PeriodicalIF":0.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12571099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145410192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolution of Surgical Management in Tetralogy of Fallot: A Historical and Contemporary Review.","authors":"Mohsin Yahya Murshid, Osama Abdulrahman, Suha Althibait","doi":"10.4103/heartviews.heartviews_55_25","DOIUrl":"10.4103/heartviews.heartviews_55_25","url":null,"abstract":"<p><p>Tetralogy of Fallot (TOF) is the most common cyanotic congenital heart disease presenting beyond the neonatal period. Since its first comprehensive description by Étienne-Louis Fallot in 1888, the management of TOF has evolved remarkably - from a universally fatal condition to one with high survival and long-term quality of life. The introduction of the Blalock-Taussig shunt in 1944 provided the first effective surgical palliation by increasing pulmonary blood flow. In the 1950s, the development of cardiopulmonary bypass enabled complete intracardiac repair, which soon became the definitive treatment. Subsequent decades saw refinements in surgical technique, including the adoption of the transatrial-transpulmonary approach and pulmonary valve-sparing strategies, aimed at preserving right ventricular (RV) function. Early primary repair, now typically performed in infancy, has become the standard of care in most centers. Despite these advances, late complications such as pulmonary regurgitation, RV dilation, arrhythmias, and reinterventions remain common, necessitating lifelong follow-up. Contemporary management includes the use of multimodality imaging, transcatheter pulmonary valve replacement (TPVR), and tailored surgical planning. Emerging technologies such as artificial intelligence and computational modeling hold promise for further improving individualized care. This review outlines the historical milestones, current best practices, and future directions in the surgical treatment of TOF, highlighting its transformation from a fatal diagnosis to a survivable chronic condition requiring multidisciplinary, lifelong care.</p>","PeriodicalId":32654,"journal":{"name":"Heart Views","volume":"26 2","pages":"126-131"},"PeriodicalIF":0.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12571101/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145410135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Potential Explanations for the Relationship Between Smoking and In-hospital Mortality in Acute Myocardial Infarction Patients.","authors":"Fatemeh Omidi","doi":"10.4103/heartviews.heartviews_130_23","DOIUrl":"10.4103/heartviews.heartviews_130_23","url":null,"abstract":"","PeriodicalId":32654,"journal":{"name":"Heart Views","volume":"26 2","pages":"136"},"PeriodicalIF":0.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12571092/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145410204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time to Thrombolysis and Outcomes in Patients with Left-sided Prosthetic Valve Thrombosis: Is Thrombolysis Worth Beyond 7 Days?","authors":"Vatsal Kayal, Puneet Aggarwal, Bhagya Narayan Pandit, Ranjit Kumar Nath, Santosh Kumar Sinha, Dheerendra Kuber","doi":"10.4103/heartviews.heartviews_98_24","DOIUrl":"10.4103/heartviews.heartviews_98_24","url":null,"abstract":"<p><strong>Background: </strong>The study aimed to evaluate the clinical outcome and complications after thrombolysis in patients with left-sided prosthetic valve thrombosis (PVT) in relation to the time of onset of symptoms.</p><p><strong>Materials and methods: </strong>This was a prospective, observational, single-center study carried out from January 2020 to June 2022 at a tertiary care center in India. A total of 50 patients with PVT were included in the study. Patients underwent thrombolysis either with streptokinase or tenecteplase as per their individual clinical status. Clinical profile and treatment outcomes were assessed.</p><p><strong>Results: </strong>PVT was more in females (64%) as compared to males (36%). The majority of the patients were in the age group of 31-40 years (38%) with a mean age of presentation being 32.7 years. Majority of the patients (39 patients) had symptom onset between 0 and 7 days (78%) while 11 patients (22%) presented beyond 7 days. Streptokinase was used for thrombolysis in 37 patients while Tenecteplase was used in 13 patients. In our study, majority of the patients 30 (60%) had a complete response to thrombolysis while 10 (20%) patients had a partial response, and no response to thrombolysis was seen in 10 (20%) patients. Hemorrhagic stroke was seen in 4 (8%) patients. Among 6 deaths, 3 were due to hemorrhagic stroke and 3 were due to cardiogenic shock.</p><p><strong>Conclusions: </strong>Early thrombolysis within 7 days of symptom onset provides a good response to thrombolysis after which the response to thrombolysis is more likely to be suboptimal.</p>","PeriodicalId":32654,"journal":{"name":"Heart Views","volume":"26 2","pages":"96-101"},"PeriodicalIF":0.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12571094/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145410285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kuwait Heart Foundation Registry of Acute Coronary Events: Design and Rationale of Large Contemporary Registry of Acute Coronary Syndromes.","authors":"Mohammad Zubaid, Mousa Akbar, Abdullah Alenezi, Fahad Alenezi, Mohammad Aljarallah, Ahmad Alkharaza, Samah Alkharji, Darar Alkhudair, Muhammad Alshammari, Abdullah Esmaiel, Ibrahim Farrag","doi":"10.4103/heartviews.heartviews_26_25","DOIUrl":"10.4103/heartviews.heartviews_26_25","url":null,"abstract":"<p><strong>Aim: </strong>The aim of this study was to describe the design and rationale of a registry of patients with acute coronary syndromes (ACSs) in Kuwait.</p><p><strong>Methods: </strong>Kuwait Heart Foundation Registry of Acute Coronary Events (KHF RACEs) is a prospective, multicenter, observational, cohort-based registry of consecutive patients admitted to hospitals in Kuwait with a working diagnosis of ACSs. The trial is registered at \"Clinical Trials.gov\" number NCT05857735 and enrollment started on May 15, 2023. It involved 8 hospitals and 124 investigators. Data were collected prospectively and entered into an online system specifically created for this registry. This included demographic data, risk factors, past medical history, medications at admission and discharge, pertinent findings on physical examination at admission, inhospital investigations, and management including cardiac catheterization and subsequent percutaneous coronary interventions. The observed outcomes included inhospital and 30-day mortality and major adverse cardiac events.</p><p><strong>Conclusion: </strong>KHF RACE is the largest contemporary ACS registry in the Middle East. It provides an example of how large multicenter registries can be carried out successfully in this part of the world. Results are expected to shed light on the adherence to guidelines in our daily practice and its influence on patients' outcomes. Several analyses of the data are planned, including the influence of age, gender, diabetes, and insurance status on outcomes. Other planned analyses will be relating to cardiac catheterization and its related outcomes.</p>","PeriodicalId":32654,"journal":{"name":"Heart Views","volume":"26 2","pages":"71-74"},"PeriodicalIF":0.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12571100/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145410314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}